

41. Darrell Maukonen, The Villages, Florida, Court of Federal Claims No: 14-0648V
42. John Poh, Bainbridge Island, Washington, Court of Federal Claims No: 14-0649V
43. Ashley M. Pietro, Linwood, New Jersey, Court of Federal Claims No: 14-0652V
44. June Reed on behalf of M. C., Shreveport, Louisiana, Court of Federal Claims No: 14-0653V
45. Karen Woolley, Buena Vista, California, Court of Federal Claims No: 14-0654V
46. George Seaberg and Darla Seaberg on behalf of Calan Seaberg, Dallas, Texas, Court of Federal Claims No: 14-0655V
47. Stephanie Kuhn on behalf of L. K., Augusta, Georgia, Court of Federal Claims No: 14-0656V
48. Carrie Hodgkinson and Chad Hodgkinson on behalf of E. H., New York, New York, Court of Federal Claims No: 14-0660V
49. Patricia Elliott, Groveland, California, Court of Federal Claims No: 14-0661V
50. Gretchen Brady Ebright, Hummelstown, Pennsylvania, Court of Federal Claims No: 14-0662V
51. Carl Silvestri and Susan Silvestri on behalf of S. S., Boston, Massachusetts, Court of Federal Claims No: 14-0666V
52. Jane Goering, Boston, Massachusetts, Court of Federal Claims No: 14-0667V
53. Aimee Deak, Boston, Massachusetts, Court of Federal Claims No: 14-0668V
54. Gaines Hearn, Birmingham, Alabama, Court of Federal Claims No: 14-0669V
55. Larry Scott Pearce, Boston, Massachusetts, Court of Federal Claims No: 14-0670V
56. Lindsey Pelton on behalf of Nickson Law Pelton, Southeast Conyers, Georgia, Court of Federal Claims No: 14-0674V
57. Holly Brannigan on behalf of K. B., Piermont, New York, Court of Federal Claims No: 14-0675V
58. Charles Storey, Eugene, Oregon, Court of Federal Claims No: 14-0676V
59. Eddie David Dukes, Summerville, South Carolina, Court of Federal Claims No: 14-0677V
60. Shirley Darlene Pardue, Chattanooga, Tennessee, Court of Federal Claims No: 14-0678V
61. Cynthia Rae Torres, Dodge City, Kansas, Court of Federal Claims No: 14-0679V
62. Edward Anthony, Dickinson, Texas, Court of Federal Claims No: 14-0680V
63. Thomas M. Tafoya on behalf of R. T., Deceased, Rio Rancho, New Mexico, Court of Federal Claims No: 14-0683V
64. Darren Rose and Heejin Jinny Rose on behalf of K. R., Tenafly, New Jersey, Court of Federal Claims No: 14-0684V
65. Shirley F. Crookshanks, Richmond, Virginia, Court of Federal Claims No: 14-0685V
66. Marta Garcia, New York, New York, Court of Federal Claims No: 14-0688V

[FR Doc. 2014-20310 Filed 8-25-14; 8:45 am]

BILLING CODE 4165-15-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Proposed Collection; 60-day Comment Request; Outcome Evaluation of the Broadening Experiences in Scientific Training (BEST) Program

SUMMARY: In compliance with the requirement of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Office of Strategic Coordination (OSC), Division of Program Coordination, Planning, and Strategic Initiatives (DPCPSI), Office of the Director (OD), the National Institutes of Health (NIH), will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.

Written comments and/or suggestions from the public and affected agencies are invited on one or more of the following points: (1) Whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) The accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) Ways to enhance the quality, utility, and clarity of the information to be collected; and (4) Ways to minimize the burden of the collection of information on those who are to respond, including

the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

To Submit Comments and For Further Information: To obtain a copy of the data collection plans and instruments, submit comments in writing, or request more information on the proposed project, contact: Dr. Patricia Labosky, Office of Strategic Coordination, Division of Program Coordination, Planning, and Strategic Initiatives, Office of the Director, NIH, 1 Center Drive, MSC 0189, Building 1, Room 214A, Bethesda, MD 20892-0189; or call 301-594-4863; or email your request, including your address to: Workforce_Award@mail.nih.gov. Formal requests for additional plans and instruments must be requested in writing.

DATES: *Comment Due Date:* Comments regarding this information collection are best assured of having their full effect if received within 60 days of the date of this publication.

Proposed Collection: Outcome Evaluation of the Broadening Experiences in Scientific Training (BEST) Program, 0925-New, Office of Strategic Coordination, Division of Program Coordination, Planning, and Strategic Initiatives, Office of the Director, National Institutes of Health (NIH).

Need and Use of Information Collection: The goal of the BEST program is to complement and broaden both doctoral and postdoctoral traditional training experiences. The evaluation study will assess three desired outcomes of the BEST Program: (1) Changes in understanding of career opportunities, confidence to make career decisions, and attitudes towards career opportunities; (2) reduction in time desired, not training, nonterminal career opportunities, and reduction in time in postdoctoral positions; (3) creation/further development of institutional infrastructure to continue BEST-like activities. The findings will be used to (1) inform the NIH Director, the BEST program staff, and the biomedical training community on the outcomes of the program; and (2) disseminate best practices across biomedical training programs and the research community.

OMB approval is requested for 3 years. There are no costs to respondents other than their time. The estimated annualized burden hours are 16,502.

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents	Number of respondents	Frequency of response	Average burden per response (in hours)	Annual hour burden
Graduate Student—Entrance Survey (online survey)	5,901	1	45/60	4,426
Graduate Student—Interim Survey (online survey)	14,753	1	20/60	4,918
Graduate Student—Graduation Survey (online survey)	3,934	1	20/60	1,311
Graduate Student—Post-graduation 2-year Follow-up Survey (online survey)	3,934	1	20/60	1,311
Postdoctoral Scientist—Entrance Survey (online survey)	3,777	1	45/60	2,833
Postdoctoral Scientist—Exit Survey (online survey)	2,518	1	20/60	839
Postdoctoral Scientist—Post-exit 2-year Follow-up Survey (online survey) ...	2,518	1	20/60	839
Principal Investigators—Annual Interview (phone—end of each year of award)	25	1	1	25

Dated: August 20, 2014.

Lawrence A. Tabak,

Deputy Director, National Institutes of Health.

[FR Doc. 2014–20268 Filed 8–25–14; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

FOR FURTHER INFORMATION CONTACT: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804; telephone: 301–496–7057; fax: 301–402–0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

SUPPLEMENTARY INFORMATION: Technology descriptions follow.

A Rabbit Anti-pT1989 ATR Monoclonal Antibody for Use in Immunoassays

Description of Technology: This technology concerns a novel

monoclonal antibody for selecting new anti-cancer compounds.

The active form of ATR (ataxia telangiectasia-mutated and Rad3-related) kinase is phosphorylated at Threonine 1989 site (T1989). The monoclonal antibody binds the phosphorylated Threonine 1989 (T1989). The phosphorylated ATR senses DNA damage response and leads to cell cycle arrest. Targeting at ATR, anti-cancer drugs may induce cancer cell death.

This technology can be applied into stable and immunoassays on multiple platforms for measuring ATR activation and inhibition and may inform therapeutic decisions for cancer treatment.

Potential Commercial Applications:

- Antibody specifically against phosphorylated ATR (at T1989 site).
- Application in assays to develop personalized medicine for pT1989 ATR-related disease.
- Application in assays for selecting measuring ATR modulation.
- Application in assays for selecting ATR inhibitors.

Competitive Advantages:

- Novel antibody against ATR phosphorylated at T1989.
 - Possibility to establish stable and effective immunoassays to select drugs specifically targeting ATR.
 - Works in western blot and IFA applications on crude (unenriched) cell lysates.
 - Works in standard processed clinical and preclinical samples.
 - Can be used to report drug activity.
- Development Stage:*
- In vitro data available.
 - In vivo data available (animal).
 - Prototype.

Inventors: Thomas D. Pfister (SAIC-Frederick), Allison M. Marrero (SAIC-Frederick), Ralph E. Parchment (SAIC-Frederick), James H. Doroshow (NCI).

Intellectual Property: HHS Reference No. E–001–2014/0—US Provisional

Application No. 61/893,070 filed 18 Oct 2013.

Licensing Contact: Surekha Vathyam, Ph.D.; 301–435–4076; vathyams@mail.nih.gov.

Monitoring the Effects of Sleep Deprivation Using Neuronal Avalanches

Description of Technology: Investigators at the National Institute of Mental Health have discovered a novel method for monitoring the effects of sleep deprivation on brain activity. Sleep deprivation has been known to adversely affect basic cognitive abilities, such as object recognition and decision making, even leading to hallucinations and epileptic seizures. This invention measures the degree of sleep deprivation and decrease in behavioral performance directly from resting brain activity. A deviation from optimal avalanche parameters correlates with duration of wakefulness and decrease in performance.

Potential Commercial Applications:

- Monitor wakefulness, reaction time.
- Potential application for monitoring sleep-deprived first-responders (e.g., military, EMT, etc.)

Competitive Advantages:

- Continuously monitors brain activity.
- Non-invasive.

Development Stage:

- In vivo data available (human).
- Prototype.

Inventors: Dietmar Plenz (NIMH), Oren Shriki (NIMH), Christian Meisel (NIMH), Giulio Tononi (Univ. Wisconsin).

Publication: Meisel C, et al. Fading signatures of critical brain dynamics during sustained wakefulness in humans. *J Neurosci.* 2013 Oct 30;33(44):17363–72. [PMID 24174669].

Intellectual Property: HHS Reference No. E–345–2013/0—US Application No. 61/866,962 filed 16 Aug 2013.

Related Technologies: HHS Reference No. E–294–2005/1–